+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Sulphonamides Market 2019-2025

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129627
Global Sulphonamides Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Topical), By Application (Urinary Tract Infection, Skin Infection, Eye Infection, Respiratory Tract Infection, Gastrointestinal Tract Infection, and Others) and Forecast, 2019-2025.

The global sulphonamides market is estimated to grow significantly during the forecast period. Increasing prevalence of infectious diseases is contributing to the demand for sulphonamides. In the US, there were 15.5 million visits to physician offices with parasitic and infectious diseases as the primary diagnosis reported in 2017. The number of new tuberculosis and meningococcal disease were 9,105 and 353, respectively. This contributes to the demand for sulphonamides as a potent drug that acts to monitor growth and proliferation of Mycobacterium tuberculosis (MTBs) by hindering the activity of both dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR).

As a class of antibiotics, sulphonamides inhibit folic acid synthesis by competing with p-aminobenzoic acid (PABA). Sulfamethoxazole (sulfonamide)–trimethoprim (diaminopyrimidine) (co-trimoxazole) has been utilized as an effective medication for the treatment of drug-resistant TB. Owing to the anti-mycobacterial mycobacterial activity, Sulphonamides are being significantly used for the TB and meningococcal treatment, which in turn, is driving the growth of the market. However, the availability of alternative drugs may hinder the growth of the market.

Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a significant share in the market in 2018 owing to the significant prevalence of infectious diseases in the region. This results in the adoption of antibacterial drugs and thereby drives the adoption of sulphonamides in the region. Asia-Pacific is estimated to witness potential growth during the forecast period owing to the increasing incidences of urinary tract infection and gastrointestinal tract infection in the region.

Some crucial players in the market include GlaxoSmithKline plc, Bayer AG, Pfizer Inc., Allergan plc, and Mylan N.V. Sulfamylon (Mafenide) by Mylan N.V. is a part of sulfa antibiotics which is available in the form of cream. It is used for prevention and treatment of wound infections among patients with severe burns. Mafenide is a drug which is applied to the skin and functions by killing bacteria that may infect an open wound. As a result, it enables to promote wound healing and minimize the risk of the bacteria spreading to surrounding skin or to the blood, which in turn, prevent a serious blood infection (sepsis).

Research Methodology

The market study of the global sulphonamides market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Sulphonamides Market Research and Analysis by Route of Administration
2. Global Sulphonamides Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the global sulphonamides market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global sulphonamides market.
  • Insights about market determinants, which are stimulating the global sulphonamides market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. GlaxoSmithKline plc Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Bayer AG Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Allergan plc Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Mylan N.V. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Sulphonamides Market by Route of Administration
5.1.1. Oral
5.1.2. Topical
5.2. Global Sulphonamides Market by Application
5.2.1. Urinary Tract Infection
5.2.2. Skin Infection
5.2.3. Eye Infection
5.2.4. Respiratory Tract Infection
5.2.5. Gastrointestinal Tract Infection
5.2.6. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AA Pharma Inc.
7.2. Abbott Laboratories
7.3. Allergan plc
7.4. Bausch Health Companies Inc.
7.5. Bayer AG
7.6. Boehringer Ingelheim International GmbH
7.7. Cipla Ltd.
7.8. DK Pharmachem Pvt. Ltd.
7.9. F. Hoffmann-La Roche AG
7.10. GlaxoSmithKline plc
7.11. Lexine Technochem Pvt. Ltd.
7.12. Mylan N.V.
7.13. Pfizer Inc.
7.14. Prudence Pharma Chem
7.15. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AA Pharma Inc.
  • Abbott Laboratories
  • Allergan plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • DK Pharmachem Pvt. Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Lexine Technochem Pvt. Ltd.
  • Mylan N.V.
  • Pfizer Inc.
  • Prudence Pharma Chem
  • Teva Pharmaceutical Industries Ltd.